India approves its first Dengue Vaccine QDENGA after DCGI clearance

India's approval of QDENGA, the country's first dengue vaccine, represents a watershed moment in public health policy and biomedical regulation. For decades, dengue has been a persistent seasonal threat, with India reporting over 200,000 cases annually and cyclical outbreaks peaking during monsoon months. The disease, caused by four distinct serotypes (DENV-1 to DENV-4) of the flavivirus transmitted by Aedes aegypti mosquitoes, has burdened both urban and rural healthcare systems, particularly in states like Kerala, Karnataka, Maharashtra, and Delhi. The Drugs Controller General of India (DCGI), functioning under the Central Drugs Standard Control Organisation (CDSCO) and the Ministry of Health and Family Welfare, granted market authorisation to QDENGA in 2024 after rigorous evaluation of Phase 3 clinical trial data from the TIDES trial, which demonstrated 80.2% efficacy against symptomatic dengue and 90.4% against hospitalisation across all serotypes. This development must be viewed against India's evolving vaccine regulatory framework. The DCGI's approval follows the 2019 New Drugs and Clinical Trials Rules, which streamlined pathways for innovative biologics while ensuring safety. Notably, QDENGA is a live-attenuated tetravalent vaccine — a technological leap from earlier candidates like Dengvaxia (Sanofi), which faced restrictions due to antibody-dependent enhancement (ADE) risks in seronegative individuals. Takeda's vaccine, by contrast, showed consistent efficacy regardless of prior dengue exposure, making it suitable for broader use. The approval aligns with India's commitment under the National Health Policy 2017 to strengthen preventive healthcare and achieve Universal Health Coverage (UHC), a goal rooted in Article 47 of the Directive Principles of State Policy, which mandates the State to raise nutrition levels and improve public health. Stakeholders span multiple domains: the Union Health Ministry will determine inclusion in the Universal Immunisation Programme (UIP), currently covering 12 vaccines; state governments will manage procurement and cold-chain logistics; and the National Technical Advisory Group on Immunisation (NTAGI) will evaluate cost-effectiveness and target age groups. Internationally, QDENGA has WHO prequalification (2023) and approvals in the EU, UK, Brazil, and Indonesia — positioning India within a global dengue control network. Economically, the vaccine could reduce the estimated $1.1 billion annual dengue burden (direct medical costs + productivity losses), while socially, it addresses health equity by protecting vulnerable populations in endemic zones. Future implications are profound. If included in UIP, India could become the largest dengue vaccination programme globally. However, challenges remain: pricing negotiations with Takeda, surveillance for long-term safety, integration with vector control programmes under the National Vector Borne Disease Control Programme (NVBDCP), and public awareness campaigns to counter vaccine hesitancy. This milestone also underscores India's growing role in global health governance — as both a major vaccine producer and a significant disease-burden country shaping regulatory precedents for the Global South.